ADMA Biologics Rebuts Misleading Short-Seller Report by Culper Research

ADMA Biologics continues to defend its position against a "misleading" report by Culper Research that triggered a significant stock decline. Legal pressure is intensifying as the Law Offices of Frank R. Cruz joined Ademi LLP in launching independent investigations into potential federal securities law violations. These probes focus on whether the company issued inaccurate statements regarding its financial results and business operations to regulatory bodies. Despite these mounting challenges, technical indicators suggest the stock remains in oversold territory, potentially setting the stage for a price reversal. Conversely, Wall Street analysts maintain their bullish outlook by raising earnings estimates, signaling confidence in the company's fundamentals despite the volatility. ADMA’s management reaffirmed its strict adherence to GAAP standards and SEC regulations, dismissing the allegations as market manipulation efforts.

Sources:globenewswire.comgurufocus.cominvesting.comintellectia.aistocktwits.commarketscreener.comperplexity.aiaktiencheck.destreetinsider.comzacks.combenzinga.comprnewswire.combusinesswire.comzacks.comzacks.comzacks.comzacks.com